LGVN
Longeveron Inc
$
0.680
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.7059
Open
0.700
VWAP
0.68
Vol
665.40K
Mkt Cap
14.15M
Low
0.6725
Amount
454.23K
EV/EBITDA(TTM)
--
Total Shares
8.04M
EV
-175.17K
EV/OCF(TTM)
--
P/S(TTM)
3.82
Longeveron Inc. is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. Lomecel-B has multiple potential mechanisms of action, encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. The Company is pursuing three pipeline indications: hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty. Lomecel-B development programs have received five distinct FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
477.00K
-20.9%
--
--
444.00K
-42.56%
--
--
411.50K
-12.07%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Longeveron Inc. (LGVN) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -52.74%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-52.74%
In Past 3 Month
4 Analyst Rating
928.66% Upside
Wall Street analysts forecast LGVN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LGVN is 7.00 USD with a low forecast of 2.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
928.66% Upside
Current: 0.680
Low
2.00
Averages
7.00
High
10.00
928.66% Upside
Current: 0.680
Low
2.00
Averages
7.00
High
10.00
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-21
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-21
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2025-03-03
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2025-03-03
Reiterates
Strong Buy
Reason
Roth MKM
Boobalan Pachaiyappan
Strong Buy
Initiates
$10
2024-12-05
Reason
Roth MKM
Boobalan Pachaiyappan
Price Target
$10
2024-12-05
Initiates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2024-11-25
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2024-11-25
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2024-11-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2024-11-04
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$10
2024-09-04
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$10
2024-09-04
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Longeveron Inc (LGVN.O) is -0.54, compared to its 5-year average forward P/E of -4.42. For a more detailed relative valuation and DCF analysis to assess Longeveron Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.42
Current PE
-0.54
Overvalued PE
-0.32
Undervalued PE
-8.52
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-4.44
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.69
Undervalued EV/EBITDA
-11.57
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
79.28
Current PS
5.30
Overvalued PS
165.71
Undervalued PS
-7.15
Financials
Annual
Quarterly
FY2025Q1
YoY :
-30.47%
381.00K
Total Revenue
FY2025Q1
YoY :
+26.67%
-5.18M
Operating Profit
FY2025Q1
YoY :
+23.48%
-5.01M
Net Income after Tax
FY2025Q1
YoY :
-78.88%
-0.34
EPS - Diluted
FY2025Q1
YoY :
+54.71%
-4.85M
Free Cash Flow
FY2025Q1
YoY :
+20.22%
72.18
Gross Profit Margin - %
FY2025Q1
YoY :
-56.81%
-744.90
FCF Margin - %
FY2025Q1
YoY :
+77.61%
-1.32K
Net Margin - %
Trading Trends
Insider
Insiders areSelling! The selling amount has increased 1320.29% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
36.8K
USD
4
6-9
Months
2.6K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders areSelling! The selling amount has increased 1320.29% over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
36.8K
USD
4
6-9
Months
2.6K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
LGVN News & Events
Events Timeline
2025-08-08 (ET)
2025-08-08
13:34:46
Longeveron announces $17.5M Class A common stock offering
2025-07-21 (ET)
2025-07-21
09:17:25
Longeveron licenses patent for stem cell technology from University of Miami
2025-07-08 (ET)
2025-07-08
09:16:50
Longeveron announces FDA approval of IND application for laromestrocel study
Sign Up For More Events
Sign Up For More Events
News
8.5
08-11NewsfilterPinnedLongeveron Announces Closing Of Up To $17.5 Million Public Offering
8.5
08-08NewsfilterLongeveron Announces Up To $17.5 Million Public Offering
9.5
08-05NewsfilterLongeveron® to Report Second Quarter 2025 Financial Results and Host Conference Call on August 13, 2025
Sign Up For More News
People Also Watch
KFFB
Kentucky First Federal Bancorp
3.174
USD
+2.72%
LRE
Lead Real Estate Co Ltd
1.530
USD
+6.25%
NRSN
Neurosense Therapeutics Ltd
1.120
USD
-6.67%
TRT
Trio-Tech International
5.590
USD
-0.07%
HUDI
Huadi International Group Co., Ltd.
1.100
USD
-4.35%
ENLV
Enlivex Therapeutics Ltd
1.570
USD
+6.80%
UTSI
UTStarcom Holdings Corp
2.395
USD
+0.84%
MXC
Mexco Energy Corp
8.430
USD
+1.08%
LVTX
LAVA Therapeutics NV
1.530
USD
+0.66%
FAQ
What is Longeveron Inc (LGVN) stock price today?
The current price of LGVN is 0.6805 USD — it has decreased -2.16 % in the last trading day.
What is Longeveron Inc (LGVN)'s business?
What is the price predicton of LGVN Stock?
What is Longeveron Inc (LGVN)'s revenue for the last quarter?
What is Longeveron Inc (LGVN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Longeveron Inc (LGVN)'s fundamentals?
How many employees does Longeveron Inc (LGVN). have?